ALCIDION GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.045 AUD | -4.26% |
|
0.00% | -40.00% |
| Apr. 18 | Alcidion Logs AU$10 Million Cash Receipts in Fiscal Q3 | MT |
| Apr. 18 | Alcidion Group Limited Provides Revenue Guidance for the Second Half of 2024 | CI |
| Sales 2024 * | 38.87M 24.94M | Sales 2025 * | 41.8M 26.82M | Capitalization | 63.1M 40.49M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M -3.85M | Net income 2025 * | -1M -642K | EV / Sales 2024 * | 1.31 x |
| Net cash position 2024 * | 12.03M 7.72M | Net cash position 2025 * | 12.3M 7.89M | EV / Sales 2025 * | 1.22 x |
| P/E ratio 2024 * |
-9.46
x | P/E ratio 2025 * |
-61
x | Employees | 191 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alcidion Group Limited
More press releases
| 1 day | -4.26% | ||
| Current month | -11.76% | ||
| 1 month | -11.76% | ||
| 3 months | -27.42% | ||
| 6 months | -55.00% | ||
| Current year | -40.00% |
1 week
0.04
0.05
1 month
0.040.05
Current year
0.040.08
1 year
0.040.13
3 years
0.040.49
5 years
0.040.49
10 years
0.030.49
| Managers | Title | Age | Since |
|---|---|---|---|
Kate Quirke
CEO | Chief Executive Officer | - | 18-07-02 |
Matt Gepp
DFI | Director of Finance/CFO | - | 21-06-06 |
Vivek Krishnan
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Sharp
BRD | Director/Board Member | - | 21-08-31 |
Victoria Weekes
BRD | Director/Board Member | - | 21-08-31 |
Rebecca Wilson
CHM | Chairman | - | 17-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.045 | -4.26% | 308 681 |
| 24-04-18 | 0.047 | +6.82% | 2,729,213 |
| 24-04-17 | 0.044 | 0.00% | 559,278 |
| 24-04-16 | 0.044 | 0.00% | 198,223 |
| 24-04-15 | 0.044 | -2.22% | 415,242 |
Delayed Quote Australian S.E., April 19, 2024 at 02:10 am EDT
More quotes
Alcidion Group Limited is a healthcare technology company. Its principal activities include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, systems integration, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a smart clinical solution based on a FHIR-event platform that facilitates multiple clinical and operational applications. Its other products include Smartpage, Patientrack, and Silverlink PCS. Smartpage is an advanced smartphone and Web-based system for hospital communication and task management, addressing the requirements of both clinical and non-clinical users. The Company services over 400 hospitals.
Sector
Software
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.047
AUD
Average target price
0.08
AUD
Spread / Average Target
+70.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.00% | 40.63M | |
| +7.52% | 3,004B | |
| +0.93% | 79.28B | |
| +4.97% | 77.94B | |
| -13.94% | 53.9B | |
| -18.60% | 50.22B | |
| +23.06% | 46.76B | |
| +12.30% | 39.49B | |
| +39.01% | 31.91B | |
| -12.62% | 23.99B |
- Stock Market
- Equities
- ALC Stock
